GSK has agreed to a $105 million settlement with 44 US states and the District of Columbia over allegations it mispromoted three drugs
GlaxoSmithKline (GSK) has agreed to a $105 million settlement with 44 US states and the District of Columbia over allegations it mispromoted three drugs.
The drugs are asthma medication Advair and anti-depressants Paxil and Wellbutrin.
The pharmaceutical giant did not admit any wrongdoing, and said the charges came from past issues.
As part of the settlement, GSK must extend its Patient First Program until 2019, which prohibits financial incentives to its sales people, and it is prohibited from paying doctors to speak about GSK’s products or attend conferences.
“This settlement requires GSK to pay a significant penalty and imposes strong new rules designed to prevent future misrepresentations of GSK products,” said California attorney general Kamala Harris in a statement.
GSK insists that many of these practices are already in place.
The US House Ethics Committee has voted to release its report on former Republican Representative…
ABC News has agreed to pay $15 million to President-elect Donald Trump to settle a…
South Korea’s parliament has voted to impeach President Yoon Suk Yeol over his failed attempt…
Israeli war planes have carried out more than 100 air strikes in Syria on December…
President-elect Donald Trump has threatened to impose 100% tariffs on the BRICS countries if they…
Syrian troops have withdrawn from the city of Aleppo following an offensive by rebels opposed…
